Vanguard Group Inc Century Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,110,082 shares of IPSC stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,110,082
Previous 2,377,494
11.25%
Holding current value
$1.2 Million
Previous $1.14 Million
3.51%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding IPSC
# of Institutions
66Shares Held
23.8MCall Options Held
33.4KPut Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$3.08 Million0.91% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.65 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.02MShares$1.15 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$971,4120.28% of portfolio
-
Casdin Capital, LLC New York, NY1.23MShares$700,0680.1% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $33.6M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...